100 related articles for article (PubMed ID: 28814158)
1. A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system.
Gavin PD; Simon LS; Schlagheck T; Smith AJ; Krishnarajah J
Pain Manag; 2017 Nov; 7(6):499-512. PubMed ID: 28814158
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxycodone transdermal patch system: a Phase I study.
Gavin PD; Simon LS; Schlagheck T; Smith AJ; Shakib S
Pain Manag; 2017 Jul; 7(4):243-253. PubMed ID: 28421874
[TBL] [Abstract][Full Text] [Related]
3. Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial.
Gavin PD; Tremper L; Smith A; Williams G; Brooker C
Pain Manag; 2017 Jul; 7(4):255-267. PubMed ID: 28415907
[TBL] [Abstract][Full Text] [Related]
4. Tocopheryl phosphate mixture (TPM) as a novel lipid-based transdermal drug delivery carrier: formulation and evaluation.
Gavin PD; El-Tamimy M; Keah HH; Boyd BJ
Drug Deliv Transl Res; 2017 Feb; 7(1):53-65. PubMed ID: 27672079
[TBL] [Abstract][Full Text] [Related]
5. Topical application of a novel oxycodone gel formulation (tocopheryl phosphate mixture) in a rat model of peripheral inflammatory pain produces localized pain relief without significant systemic exposure.
Smith MT; Wyse BD; Edwards SR; El-Tamimy M; Gaetano G; Gavin P
J Pharm Sci; 2015 Jul; 104(7):2388-96. PubMed ID: 25995048
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study.
Adams MP; Ahdieh H
Pharmacotherapy; 2004 Apr; 24(4):468-76. PubMed ID: 15098800
[TBL] [Abstract][Full Text] [Related]
7. Oxymorphone: a review.
Prommer E
Support Care Cancer; 2006 Feb; 14(2):109-15. PubMed ID: 16317569
[TBL] [Abstract][Full Text] [Related]
8. Oral extended-release oxymorphone: a new choice for chronic pain relief.
Matsumoto AK
Expert Opin Pharmacother; 2007 Jul; 8(10):1515-27. PubMed ID: 17661733
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and behavioral effects of oxymorphone after intravenous and subcutaneous administration to healthy dogs.
KuKanich B; Schmidt BK; Krugner-Higby LA; Toerber S; Smith LJ
J Vet Pharmacol Ther; 2008 Dec; 31(6):580-3. PubMed ID: 19000282
[No Abstract] [Full Text] [Related]
10. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
11. Intranasal absorption of oxymorphone.
Hussain MA; Aungst BJ
J Pharm Sci; 1997 Aug; 86(8):975-6. PubMed ID: 9269879
[TBL] [Abstract][Full Text] [Related]
12. Letter to the editor. Use of oral oxymorphone.
Kerwin R
Consult Pharm; 2007 Dec; 22(12):972-3; author reply 973-4. PubMed ID: 18210674
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs.
Smith LJ; Kukanich BK; Krugner-Higby LA; Schmidt BH; Heath TD
Vet Anaesth Analg; 2013 Sep; 40(5):537-45. PubMed ID: 23601353
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oxymorphone in cats.
Siao KT; Pypendop BH; Stanley SD; Ilkiw JE
J Vet Pharmacol Ther; 2011 Dec; 34(6):594-8. PubMed ID: 21323677
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of oxymorphone.
Vadivelu N; Maria M; Jolly S; Rosenbloom J; Prasad A; Kaye AD
J Opioid Manag; 2013; 9(6):439-52. PubMed ID: 24481932
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
[TBL] [Abstract][Full Text] [Related]
17. Oral oxymorphone (Opana).
Med Lett Drugs Ther; 2007 Jan; 49(1251):3-4. PubMed ID: 17179898
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
19. Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs.
Smith LJ; Krugner-Higby L; Trepanier LA; Flaska DE; Joers V; Heath TD
J Vet Pharmacol Ther; 2004 Oct; 27(5):369-72. PubMed ID: 15500576
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.
Kaiko RF; Benziger DP; Fitzmartin RD; Burke BE; Reder RF; Goldenheim PD
Clin Pharmacol Ther; 1996 Jan; 59(1):52-61. PubMed ID: 8549034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
